SDMHF Stock Chart & Stats
$230.18
$1.00(0.52%)
At close: 4:00 PM EDT
$230.18
$1.00(0.52%)
Day’s Range― - ―
52-Week Range$176.98 - $264.40
Previous CloseN/A
Volume155.00
Average Volume (3M)2.69K
Market Cap
$23.62B
Enterprise Value$19.88B
Total Cash (Recent Filing)$203.90M
Total Debt (Recent Filing)$2.40B
Price to Earnings (P/E)72.6
Beta0.87
Next Earnings
Oct 22, 2026EPS Estimate
1.36Next Dividend Ex-DateN/A
Dividend Yield0.33%
Share Statistics
EPS (TTM)3.02
Shares Outstanding97,330,410
10 Day Avg. Volume310
30 Day Avg. Volume2,689
Financial Highlights & Ratios
PEG Ratio1.51
Price to Book (P/B)5.00
Price to Sales (P/S)6.89
P/FCF Ratio140.53
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue6.61
Enterprise Value/Gross Profit14.74
Enterprise Value/Ebitda22.42
Forecast
1Y Price Target
$267.65Price Target Upside16.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)5.6
Revenue Forecast (FY)$3.51B
Bulls Say, Bears Say
Bulls Say
Revenue RecoveryThe sharp TTM revenue rebound indicates that demand and operating activity are recovering across Sartorius Stedim Biotech’s bioprocessing portfolio. Sustained revenue improvement can support better fixed-cost absorption, strengthen customer engagement, and provide a foundation for renewed earnings growth.
Recurring Consumables ModelFrequent replacement of single-use bags, assemblies, filters, tubing, and connectors creates a recurring revenue stream alongside equipment sales. This installed-base dynamic can deepen customer relationships, improve revenue visibility, and support durable demand as biopharmaceutical production continues.
Improved LeverageThe materially lower debt-to-equity ratio indicates a more balanced capital structure and greater financial flexibility than in 2023. Improved leverage should make it easier to fund product development, support customers, and manage cyclical biopharma capital spending without the same balance-sheet pressure.
Bears Say
Depressed ProfitabilityAlthough revenue has recovered, net profitability remains far below its prior peak, showing that volume growth has not yet translated into full earnings normalization. Persistently lower margins could constrain internal investment, reduce operating resilience, and leave results more sensitive to execution challenges.
Lower Gross MarginsThe decline in gross margin suggests the current recovery is occurring with weaker economics than during the company’s strongest years. Unless margins improve, additional revenue may generate less incremental profit, limiting operating leverage and delaying a return to the business’s earlier profitability profile.
Weak Cash ConversionFree cash flow has improved from a weak base, but conversion remains low relative to reported earnings and operating cash flow is below recent annual levels. This inconsistency can limit self-funded growth, reduce capital-allocation flexibility, and make earnings quality less dependable during the recovery.
Sartorius Stedim Biotech News
SDMHF FAQ
What was Sartorius Stedim Biotech’s price range in the past 12 months?
Sartorius Stedim Biotech lowest stock price was $176.98 and its highest was $264.40 in the past 12 months.
What is Sartorius Stedim Biotech’s market cap?
Sartorius Stedim Biotech’s market cap is $23.62B.
When is Sartorius Stedim Biotech’s upcoming earnings report date?
Sartorius Stedim Biotech’s upcoming earnings report date is Oct 22, 2026 which is in 5 days.
How were Sartorius Stedim Biotech’s earnings last quarter?
Sartorius Stedim Biotech released its earnings results on Jul 23, 2026. The company reported $1.402 earnings per share for the quarter, missing the consensus estimate of $1.416 by -$0.015.
Is Sartorius Stedim Biotech overvalued?
According to Wall Street analysts Sartorius Stedim Biotech’s price is currently Undervalued.
Does Sartorius Stedim Biotech pay dividends?
Sartorius Stedim Biotech pays a Annually dividend of $0.801 which represents an annual dividend yield of 0.33%. See more information on Sartorius Stedim Biotech dividends here
What is Sartorius Stedim Biotech’s EPS estimate?
Sartorius Stedim Biotech’s EPS estimate is 1.36.
How many shares outstanding does Sartorius Stedim Biotech have?
Sartorius Stedim Biotech has 97,330,410 shares outstanding.
What happened to Sartorius Stedim Biotech’s price movement after its last earnings report?
Sartorius Stedim Biotech reported an EPS of $1.402 in its last earnings report, missing expectations of $1.416. Following the earnings report the stock price went down -3.413%.
Which hedge fund is a major shareholder of Sartorius Stedim Biotech?
Currently, no hedge funds are holding shares in SDMHF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sartorius Stedim Biotech
Sartorius Stedim Biotech S.A., a global entity and a subsidiary of Sartorius AG, delivers critical instruments, consumables, and services tailored for the biopharmaceutical industry. Their extensive product portfolio includes fundamental components like cell lines, cell culture media, and bioreactors, alongside comprehensive solutions for separation, purification, and concentration processes. They also provide specialized systems for the safe storage and transport of biological intermediates and finished products. For advanced applications, particularly in cell and gene therapy, the company offers both single-use and reusable hollow-fiber membrane devices and presterilized assemblies. Beyond physical products, their service offerings cover vital bioprocessing steps such as cell cultivation, fermentation, filtration, purification, and fluid management, in addition to cell harvesting and broader solutions for intensified bioprocesses. Furthermore, Sartorius Stedim Biotech provides advanced data analytics software designed to model and optimize biopharmaceutical development and production workflows. Serving a diverse customer base, including pharmaceutical, food, and chemical manufacturers, as well as research and development laboratories, the company was founded in 1870 and operates from its headquarters in Aubagne, France.
SDMHF Stock 12 Month Forecast
Average Price Target
$267.65
▲(16.28% Upside)
Technical Analysis
Ownership Overview
― Insiders
3.01% Mutual Funds
<0.01% Other Institutional Investors
93.36% Public Companies and
Individual Investors